Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities

Next Previous
X
Search
Trial Profile

A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Melatonin (Primary)
  • Indications Insomnia; Sleep disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors NEURIM Pharmaceuticals

    • Most Recent Events

    • 05 Nov 2018 According to a Neurim Pharmaceuticals media release, SLENYTO(PEDPRM) WAS APPROVED BY EMA FOR THE TREATMENT OF INSOMNIA IN CHILDREN AND ADOLESCENTS AGED 2-18 WITH AUTISM SPECTRUM DISORDER (ASD) AND / OR SMITH-MAGENIS SYNDROME, WHERE SLEEP HYGIENE MEASURES HAVE BEEN INSUFFICIENT
    • 30 Jul 2018 Results presented in a Neurim Pharmaceuticals media release.
    • 30 Jul 2018 According to a Neurim Pharmaceuticals media release, the CHMP recommendation is based on results of Slenyto comprehensive data package demonstrating short and long-term (2 years) efficacy and safety of this child-appropriate, easy-to-swallow drug for insomnia in ASD children.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top